RE: From 2007 NRI have to agree also. Moving the trials along a little faster without dilution to the float has to be good! All the closer to the big pay day. Shows smart management to be creative without throwing the shareholders under the bus. With Chloe stating they are going to announce the enrollment very soon for the trials, this is moving along very nicely. No doubt they are under the microscope of big Pharma which bodes well for share holders.
The Program will provide SCT with additional low-cost capital to reach and potentially accelerate our clinical and R&D milestones without increasing overall dilution to shareholders."
GLTA Molybucks